Valproic Acid
Bipolar Depression
Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Ewha Womans University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01543139CT.gov Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression | — | Withdrawn | — | — | — |
NCT01587066CT.gov Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression | — | Withdrawn | — | — | — |
NCT00857584CT.gov Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy | — | Completed | — | — | — |
NCT00868452CT.gov Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on) | — | Completed | — | — | — |
NCT00203528CT.gov Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar Depression
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Valproic Acid (this asset) | Ewha Womans University | Approved | BB · 71 |
| Lurasidone | NeuroRx, Inc. | P4 | A |
| Lithium, Elemental | Dr. Inge Winter | P4 | BBB |
| Quetiapine | Dr. Inge Winter | P4 | BBB |
| Lamotrigine | Stony Brook University | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Joshua Rosenblat | P4 | BBB |
| Nrx-101 | NeuroRx, Inc. | P3 | BBB |
| Escitalopram | Dr. Inge Winter | P4 | BBB |
| Minocycline | Massachusetts General Hospital | P4 | BB |
+42 more in the Bipolar Depression cohort
Other indications for Valproic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar I Disorder | — | P4 | BBB · 74 |
| Epilepsy | — | P4 | BBB · 73 |
| Bipolar Disorder | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Valproic Acid in Bipolar Depression. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/valproic-acid-bipolar-depression
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →